TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced the appointment of Jack E. Stover to its Board of Directors, where he will serve on the Audit Committee and the Nominating Committee. Dr. Magda Marquet steps down from the Audit Committee. Mr. Stover brings more than 30 years of executive leadership experience across public and private life sciences companies, with a background spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation. He is expected to contribute operational, financial, and strategic expertise as TransCode advances its RNA and immuno-oncology pipeline for the treatment of high-risk and advanced cancers.
The appointment comes at a critical time for TransCode, a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a unique and well-documented biomarker of metastasis. TransCode also has a portfolio of other first-in-class RNA therapeutic candidates designed to overcome RNA delivery challenges, potentially unlocking therapeutic access to novel genetic targets relevant to treating various cancers.
Mr. Stover's extensive experience is expected to bolster TransCode's strategic direction as it navigates the complexities of drug development and capital markets. His previous roles have included executive positions in both public and private life sciences companies, providing him with a comprehensive understanding of the industry's financial and operational landscape. The addition of Mr. Stover to the board aligns with TransCode's mission to advance its pipeline and bring innovative RNA-based therapies to patients with high-risk cancers.
For more details, the full press release is available at https://ibn.fm/gQDuo. Investors seeking the latest news and updates on TransCode can visit the company's newsroom at https://ibn.fm/RNAZ.
